EN DE
Watch Clal Biotechnology Industries Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Clal Biotechnology Industries Ltd (CBI) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Clal Biotechnology Industries Ltd stock ILS 0.15, price ILS 0.22, that is 29.4% below the price, quality 47 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare Il · ISIN IL0011042806

CB Clal Biotechnology Industries Ltd logo Thin data Nov 10, 2026

Clal Biotechnology Industries Ltd

CBI · TA
Expensive, weak quality

Our calculation puts a fair price 29% below what the stock costs today.

Low debt
Quality 47/100
Mixed Growth (revenue 5y +32.3 %/yr in ILS)
Revenue last quarter 54% below a year ago.
Fair value 0.1547 ILS · Overvalued
Negative free cash flow
Trails peers (3/8)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Clal Biotechnology Industries Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

2.47 ILS 0.2170 ILS Fair Value 0.1547 ILS Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 0.2170 ILS – 2.47 ILS · fair‑value band 0.1160 ILS – 0.1934 ILS · the 0.2190 ILS price screens above the 0.1547 ILS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Clal Biotechnology Industries in your weekly email

Every Wednesday you see whether Clal Biotechnology Industries is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing.

Show moreShow less

It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to invest in companies based in United States, and Israel.

It takes a seat on the board of directors of the companies it invests in. It invests through personal capital of its management. The firm acts as a lead investor and major shareholder in its portfolio companies.

Clal Biotechnology Industries Ltd. was founded in July, 1998 and is based in Tel Aviv, Israel. It operates as a former subsidiary of Clal Industries and Investments Ltd.

Stock analysis

Clal Biotechnology Industries Ltd (CBI) currently trades at 0.2190 ILS, while our estimate is 0.1547 ILS, 29% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 0.1160 ILS (bear) to 0.1934 ILS (bull), the price of 0.2190 ILS sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Clal Biotechnology Industries Ltd reported revenue of 835K ILS in FY2025 versus 224K ILS in FY2021, a compound +39.0%/yr. Reported net income was −13.3M ILS in FY2025.

Key figures

Market cap 34.3M ILS Micro · EPS (TTM) −0.0600 ILS · Return on equity −64.3% · Return on assets (EBIT) −18.5% (5-year average) · Operating margin −125% · Revenue (TTM) −118K ILS · Revenue growth (YoY) −54.2% · Free cash flow −4.1M ILS.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −29%, CBI screens richer than that median.

Fair Value

Bear 0.1160 ILS Fair Value 0.1547 ILS Bull 0.1934 ILS
Price 0.2190 ILS · Downside -29.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 71
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 36
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 58
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+92.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.3%
Start year 2020 (pandemic). Over 10 years: −28.9% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−70.5% (2019) → −2,205.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CBI screens overvalued: fair value 29% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Clal Biotechnology Industries Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Above median
Fair Value upside −29.4% · Below median
Profitability
Return on assets −31.8% · Below median
Operating margin (12 months) −125.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −54.2% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.53× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs CBI
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs CBI
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs CBI
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs CBI
argenx SE ARGX $971.55 $908.40 −7% vs CBI
CSL Limited CSL A$201.68 A$181.40 −10% vs CBI
Moderna, Inc MRNA $250.83 $158.70 −37% vs CBI
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs CBI
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs CBI
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs CBI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Clal Biotechnology Industries Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Clal Biotechnology Industries Ltd Fair Value". https://www.fairvalue-calculator.com/stock/CBI

Frequently asked questions

Is Clal Biotechnology Industries Ltd (CBI) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 0.1547 ILS versus a price of 0.2190 ILS, about 29% lower (overvalued).
What is the fair value of CBI?
Our estimate for Clal Biotechnology Industries Ltd is 0.1547 ILS (as of Nov 10, 2026), built from audited fundamentals. The current price: 0.2190 ILS.
What is the quality score of CBI?
Clal Biotechnology Industries Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Clal Biotechnology Industries Ltd (CBI)?
Our calculated price target is the estimate of 0.1547 ILS (as of Nov 10, 2026). Cautious scenario 0.1160 ILS, optimistic scenario 0.1934 ILS. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Clal Biotechnology Industries Ltd stock forecast for 2026?
Our estimate puts fair value at 0.1547 ILS, about 29% lower versus a price of 0.2190 ILS (overvalued). Cautious scenario 0.1160 ILS, optimistic scenario 0.1934 ILS. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Clal Biotechnology Industries Ltd (CBI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Clal Biotechnology Industries Ltd it is 0.1547 ILS per share (as of Nov 10, 2026), against a price of 0.2190 ILS.
Is Clal Biotechnology Industries Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CBI trades above its calculated fair value: price 0.2190 ILS, fair value 0.1547 ILS, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CBI?
No. The price is what the market pays today (0.2190 ILS); the fair value is what the company's own numbers justify (0.1547 ILS). For Clal Biotechnology Industries Ltd the two are 0.0643 ILS per share apart. That gap is exactly why we show both numbers side by side.
How much is Clal Biotechnology Industries Ltd worth?
The market values Clal Biotechnology Industries Ltd at about 34.3M ILS (market capitalisation, as of Nov 10, 2026). Per share that is 0.2190 ILS; our models calculate a fair value of 0.1547 ILS per share.
What do the bullish and bearish scenarios say about CBI?
Our models span a range for Clal Biotechnology Industries Ltd: cautious scenario 0.1160 ILS, base 0.1547 ILS, optimistic 0.1934 ILS per share (as of Nov 10, 2026, price 0.2190 ILS). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Clal Biotechnology Industries Ltd (CBI)?
Balance-sheet figures for Clal Biotechnology Industries Ltd (as of Nov 10, 2026): return on equity −64.3%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is CBI from its 52-week high?
Clal Biotechnology Industries Ltd trades at 0.2190 ILS, about 37% below its 52-week high of 0.3490 ILS and 1% above the low of 0.2170 ILS (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1547 ILS is for.
Which stocks are comparable to Clal Biotechnology Industries Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Clal Biotechnology Industries Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 0.2190 ILS, calculated fair value 0.1547 ILS (−29%), Quality Score 47/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Clal Biotechnology Industries Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Clal Biotechnology Industries Ltd (CBI)?
The closing price on Nov 10, 2026 was 0.2190 ILS. Our estimate is 0.1547 ILS, about 29% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Clal Biotechnology Industries Ltd right now?
The price sits above even our optimistic bull case (0.1934 ILS). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Clal Biotechnology Industries Ltd

How large is the market capitalisation of Clal Biotechnology Industries Ltd (CBI)?
The market capitalisation of Clal Biotechnology Industries Ltd is 34.3M ILS. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Clal Biotechnology Industries Ltd (CBI)?
Earnings per share at Clal Biotechnology Industries Ltd are −0.0600 ILS. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Clal Biotechnology Industries Ltd (CBI)?
The return on equity (ROE) of Clal Biotechnology Industries Ltd is −64.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Clal Biotechnology Industries Ltd (CBI)?
On an EBIT basis the return on assets of Clal Biotechnology Industries Ltd is −18.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Clal Biotechnology Industries Ltd (CBI)?
The operating margin of Clal Biotechnology Industries Ltd is −125% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much revenue does Clal Biotechnology Industries Ltd (CBI) generate?
Clal Biotechnology Industries Ltd generates revenue of −118K ILS (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How fast is revenue growing at Clal Biotechnology Industries Ltd (CBI)?
Revenue at Clal Biotechnology Industries Ltd is growing −54.2% versus a year earlier (3y avg +31.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Clal Biotechnology Industries Ltd (CBI) generate?
The free cash flow of Clal Biotechnology Industries Ltd is −4.1M ILS (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Clal Biotechnology Industries Ltd (CBI) carry?
The net debt of Clal Biotechnology Industries Ltd is 16.1M ILS (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Clal Biotechnology Industries Ltd in the live analysis

One click puts Clal Biotechnology Industries Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.